Security key
84833T103
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO)
CUSIP: 84833T103
Q3 2023 13F Holders as of 30 Sep 2023
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 14,186,051
- Total 13F value
- $17,161,812
- Share change
- -177,083
- SEC-reported price per share
- $1.21
- Number of holders
- 53
- Value change
- -$230,667
- Number of buys
- 15
- Number of sells
- 21
- Shares outstanding
- 55,705,828
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2023
Institutions
53
Top holders
10
SPRO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Spero Therapeutics, Inc. SEC filings
Spero Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 84833T103
Recent filing periods:
Ownership snapshot
Top reported holders of SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Anson Funds Management LP
Disclosed value leader
Anson Funds Management LP
Comparable rows
15/15
Latest evidence
30 Jun 2023
13F
Lead comparable stake: 6.2%
Showing 1-6 of 15 holder rows.
Quick read
Anson Funds Management LP leads the comparable SEC ownership view at 6.2%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Anson Funds Management LP's linked filing trail.
Comparable ownership
Top 5
Anson Funds Management LP
6.2%
VANGUARD GROUP INC
2.7%
Atlas Venture Associates IX, LLC
2.4%
Atlas Venture Life Science Adviso...
1.8%
Alphabet Inc.
1.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Anson Funds Management LP |
13F
Company
|
6.2%
|
$4,995,050
3,444,862 shares
|
— | 30 Jun 2023 |
| VANGUARD GROUP INC |
13F
Company
|
2.7%
|
$2,213,387
1,526,474 shares
|
— | 30 Jun 2023 |
| Atlas Venture Associates IX, LLC |
13F
Company
|
2.4%
|
$1,962,289
1,353,303 shares
|
— | 30 Jun 2023 |
| Atlas Venture Life Science Advisors, LLC |
13F
Company
|
1.8%
|
$1,469,485
1,013,438 shares
|
— | 30 Jun 2023 |
| Alphabet Inc. |
13F
Company
|
1.6%
|
$1,290,469
889,979 shares
|
— | 30 Jun 2023 |
| Murchinson Ltd. |
13F
Company
|
1.4%
|
$1,105,915
762,700 shares
|
— | 30 Jun 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
53
Shares
14,186,051
Rows available
53
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2023 vs Q2 2023 Across Filers
Q2 2023 holders
56
Q3 2023 holders
53
Holder diff
-3
| Investor | Q2 2023 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q2 2023 value | Q3 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend